Edaravone Mitigates Hippocampal Neuronal Death and Cognitive Dysfunction by Upregulating BDNF Expression in Neonatal...

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• Neonatal hypoxic-ischemic encephalopathy (HIE) causes severe neurological injury and long-term cognitive deficits in infants.
• Brain-derived neurotrophic factor (BDNF) plays a critical role in neuronal survival, growth, and cognitive function.
• Edaravone (EDA), a free radical scavenger, shows potential for neuroprotection.

Purpose of the Study:

• To investigate the neuroprotective effects of Edaravone (EDA) in a neonatal rat model of HIE.
• To elucidate the role of brain-derived neurotrophic factor (BDNF) in mediating EDA's neuroprotective effects.
• To assess the impact of EDA and BDNF on cognitive function following HIE.

Main Methods:

• Neonatal rats underwent hypoxic-ischemic insult using the Rice-Vannucci model.
• EDA was administered post-insult; some rats received intrahippocampal BDNF knockdown via lentiviral vectors.
• Neuronal survival, apoptosis, BDNF expression (ELISA), and cognitive function (Morris water maze, Y maze) were assessed.

Main Results:

• EDA treatment significantly reduced neuronal apoptosis and increased neuronal survival in the hippocampus.
• EDA administration elevated BDNF expression levels in HIE rats.
• The neuroprotective and cognitive benefits of EDA were diminished in rats with BDNF knockdown.

Conclusions:

• Edaravone (EDA) demonstrates significant neuroprotective effects against HIE in neonatal rats.
• EDA's therapeutic benefits are primarily mediated through the upregulation of brain-derived neurotrophic factor (BDNF).
• These findings support EDA as a potential therapeutic agent for HIE, emphasizing BDNF's crucial role in recovery.